Clinically, elevated pretreatment CXCL12 levels (≥1.5 ng/mL) and post-treatment increases in CXCL12 are associated with reduced responsiveness to radiotherapy, suggesting that CXCL12 may mediate tumor evasion from cytotoxic therapies (41, 42). Here, CXCL12 is linked to neoplasm.